Glycopyrrolate in children

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Antisialagogue medications are crucial for managing secretions during anesthesia.
• Atropine and glycopyrrolate are commonly used, but their efficacy and side effect profiles differ based on administration route and timing.

Purpose of the Study:

• To compare the antisialagogue effects and side effects of intravenous glycopyrrolate versus intravenous and oral atropine.
• To evaluate the impact on body temperature, heart rate, cardiac arrhythmias, and postoperative restlessness.

Main Methods:

• A comparative study involving three groups of patients undergoing anesthesia.
• Group 1: Intravenous glycopyrrolate (10 µg/kg) at induction.
• Group 2: Intravenous atropine (20 µg/kg) at induction.
• Group 3: Oral atropine (30 µg/kg) 90 minutes before operation.
• Measurements included pharyngeal secretions, axillary temperature, heart rate, cardiac arrhythmia frequency, and postoperative restlessness.

Main Results:

• Patients receiving oral atropine experienced increased pharyngeal secretions, lower heart rates, and a higher frequency of cardiac arrhythmias compared to intravenous administration.
• Intravenous glycopyrrolate demonstrated significantly reduced intraoperative secretions.
• No significant differences were noted in body temperature or postoperative restlessness between the groups.

Conclusions:

• Intravenous glycopyrrolate is a more effective antisialagogue agent during anesthesia than oral or intravenous atropine.
• Oral atropine administration is associated with increased secretions and a higher incidence of cardiac arrhythmias, suggesting potential risks.